臨床試驗生物樣本庫和存檔解決方案的全球市場：按產品、階段和產品劃分的市場規模和份額分析 - 產業需求預測（截至 2030 年）

全球臨床生物樣本庫和檔案解決方案市場在 2023 年產生收入 39.852 億美元，預計將以 8.2% 的複合年增長率增長，到 2030 年達到 69.166 億美元。

這些市場趨勢是由越來越多的公司提供各種服務以及外包儲存和其他冷鏈流程的趨勢推動的，以便將必要的資源集中在藥物開發上。這是由於以下事實：它正在變得越來越強。

此外，儲存和運輸技術不斷發展，結合生物儲存的監管需求和該領域的當前趨勢，可以極大地幫助節省金錢、時間和精力。

臨床試驗生物儲存庫和存檔解決方案產業正在蓬勃發展，使用的軟體提供了複雜的實驗室資訊管理系統的功能，該系統旨在支援實驗室樣本和資訊管理。這是由於用於編譯數據以簡化流程的廉價設備的可用性不斷增加報告。

此外，在臨床試驗過程中會創建多方面的數據，這些資訊的管理和所有生物樣本庫程式使此類軟體變得至關重要，從而為存檔解決方案的提供者創造了機會。

以階段來看，III期類別在2023年佔營收份額最大，為45%，預計未來將維持其主導地位。 這是因為 III 期研究使用大量標本和樣本進行長期研究，導致對臨床試驗生物樣本庫和檔案解決方案的需求增加。

2023年，北美地區將佔據最大份額，達到55%，預計該地區將繼續佔據主導地位。 這主要是由於臨床試驗數量的增加、全球市場領導者的存在以及該地區先進技術的使用。 此外，大量服務提供者、CRO 和生物製藥公司的存在也增加了市場成長潛力。

因此，這種市場趨勢是由提供各種服務的公司數量增加以及外包存儲和其他冷鏈流程以將必要的資源集中在藥物開發上的趨勢不斷增長所推動的。這可能是因為這已成為可能。

本報告分析了全球臨床試驗生物樣本庫和檔案解決方案市場，包括市場的基本結構和最新情況、主要推動和限制因素以及全球、按地區和主要國家的市場規模趨勢。我們調查展望（基於金額，2017-2030）、按產品、階段（階段）和提供內容劃分的詳細趨勢、市場競爭現狀以及主要公司概況。

目錄

第一章研究範圍

第二章研究方法

第 3 章執行摘要

第 4 章市場指標

第五章產業展望

• 市場動態
  • 趨勢
  • 促進因素
  • 抑制因素/挑戰
  • 促進/抑制因子影響分析
• 新型冠狀病毒感染 (COVID-19) 的影響
• 波特五力分析

第六章世界市場

• 摘要
• 市場收入：依產品分類（2017-2030 年）
• 市場收入：愛別（2017-2030 年）
• 市場收入：依產品劃分（2017-2030 年）
• 市場收入：按地區劃分（2017-2030 年）

第七章北美市場

• 摘要
• 市場收入：依產品分類（2017-2030 年）
• 市場收入：愛別（2017-2030 年）
• 市場收入：依產品劃分（2017-2030 年）
• 市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第 11 章中東與非洲 (MEA) 市場

第12章美國市場

• 摘要
• 市場收入：依產品分類（2017-2030 年）
• 市場收入：愛別（2017-2030 年）
• 市場收入：依產品劃分（2017-2030 年）

第十三章加拿大市場

第14章德國市場

第十五章法國市場

第十六章英國市場

第十七章義大利市場

第十八章西班牙市場

第十九章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

• 市場參與者及其產品列表
• 主要公司的競爭基準
• 各大公司的產品基準
• 近期策略發展狀況

第30章公司簡介

• Azenta Life Sciences
• Thermo Fisher Scientific Inc.
• Precision Medicine Group LLC
• Medpace Inc.
• Labcorp Drug Development
• American Type Culture Collection
• IQVIA Inc.
• LabConnect Inc.

第31章附錄

In 2023, the global clinical trial biorepository & archiving solutions market generated revenue of USD 3,985.2 million, which is expected to grow at a compound annual growth rate of 8.2% to reach USD 6,916.6 million by 2030.

This growth of the market can be credited to the rising count of companies offering an extensive variety of services and the growing trend of outsourcing storage and other cold-chain processes so that the essential resources can concentrate more on medicinal development.

Furthermore, storage and transport techs are constantly advancing, which, combined with the l regulatory needs on bio-storage and the present trends in this space, can enormously help in saving money, time, and effort.

The clinical trial biorepository & archiving solutions industry is rising quickly because of the improvement in the obtainability of less expensive devices to compile data, for streamline reporting, using software that provides the functionality of a combined laboratory information management system made to aid in managing laboratory samples and information.

Furthermore, multifaceted data is created during trials, and the managing of such information and all the biorepository procedures makes such software essential, therefore creating an opportunity for the providers of archiving solutions.

On the basis of phase, the phase III category accounted for the largest revenue share, of 45%, in 2023, and it is further expected to maintain its dominance in the future. It is due to the fact that a significant number of specimens and samples are used by Phase III studies for long-term research, leading to increased demand for biorepository and archive solutions from clinical trials.

In phase III of the clinical trial process, researchers and scientists will evaluate the efficacy and safety of novel treatments. The number of patients participating for a long time is very high among the majority of phase III clinical studies. Besides that, because of the high number of people involved for a long time, this stage is more likely to be affected by short- and long-term side effects.

In 2023, the North American region dominated the clinical trial biorepository & archiving solutions market with the largest share of 55%, and the region is also estimated to continue with the dominance in the future. This is mainly because of the rising number of clinical trials, the presence of global market leaders, and the usage of progressive techs in the region. Furthermore, the presence of a huge count of service providers, CROs, and biopharmaceutical businesses enhances the market growth potential.

Hence, this growth of the market can be credited to the rising count of companies offering an extensive variety of services and the growing trend of the outsourcing of storage and other cold-chain processes, so that the essential resources can concentrate more on medicinal development.

Top Providers of Clinical Trial Biorepository & Archiving Solutions Are:

Azenta US Inc.

Thermo Fisher Scientific Inc.

Precision Medicine Group LLC

Medpace Inc.

Labcorp Drug Development

American Type Culture Collection

IQVIA Inc.

LabConnect Inc.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by phase
  • 1.4.3. Market size breakdown, by offering
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Phase (2017-2030)
• 6.4. Market Revenue, by Offering (2017-2030)
• 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Phase (2017-2030)
• 7.4. Market Revenue, by Offering (2017-2030)
• 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Phase (2017-2030)
• 8.4. Market Revenue, by Offering (2017-2030)
• 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Phase (2017-2030)
• 9.4. Market Revenue, by Offering (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Phase (2017-2030)
• 10.4. Market Revenue, by Offering (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Phase (2017-2030)
• 11.4. Market Revenue, by Offering (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Phase (2017-2030)
• 12.4. Market Revenue, by Offering (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Phase (2017-2030)
• 13.4. Market Revenue, by Offering (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Phase (2017-2030)
• 14.4. Market Revenue, by Offering (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Phase (2017-2030)
• 15.4. Market Revenue, by Offering (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Phase (2017-2030)
• 16.4. Market Revenue, by Offering (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Phase (2017-2030)
• 17.4. Market Revenue, by Offering (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Phase (2017-2030)
• 18.4. Market Revenue, by Offering (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Phase (2017-2030)
• 19.4. Market Revenue, by Offering (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Phase (2017-2030)
• 20.4. Market Revenue, by Offering (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Phase (2017-2030)
• 21.4. Market Revenue, by Offering (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Phase (2017-2030)
• 22.4. Market Revenue, by Offering (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Phase (2017-2030)
• 23.4. Market Revenue, by Offering (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Phase (2017-2030)
• 24.4. Market Revenue, by Offering (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Phase (2017-2030)
• 25.4. Market Revenue, by Offering (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Phase (2017-2030)
• 26.4. Market Revenue, by Offering (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Phase (2017-2030)
• 27.4. Market Revenue, by Offering (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Phase (2017-2030)
• 28.4. Market Revenue, by Offering (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Azenta Life Sciences
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Thermo Fisher Scientific Inc.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Precision Medicine Group LLC
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Medpace Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Labcorp Drug Development
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. American Type Culture Collection
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. IQVIA Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. LabConnect Inc.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports